is...(Watching)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HYII UP 50% ON HUGE UPDATE!
$HYII up 50 % !
WOW could be huge IMO !
$HYII HUGE UPDATE OUT
“We are very excited to announce our plans to expand the scope of our Plateada Project. We are confident that through a possible grant by ENAMI and our efforts to produce higher concentration copper sulfide, we will be able to double the previous monthly revenue of $100,000 generated from the property. We expect to begin generating cash flow from Plateada within the next month and be profitable within six months,” commented All Grade Mining’s CEO, Gary Kouletas.
$HYII huge update !
“We are very excited to announce our plans to expand the scope of our Plateada Project. We are confident that through a possible grant by ENAMI and our efforts to produce higher concentration copper sulfide, we will be able to double the previous monthly revenue of $100,000 generated from the property. We expect to begin generating cash flow from Plateada within the next month and be profitable within six months,” commented All Grade Mining’s CEO, Gary Kouletas.
$CEYY huge news out !
Fresh Start Private Management, Inc. Announces Alcohol Treatment Program Now Available in Nebraska
$TPNI! NEWS OUT!
$TPNI ON HIGH ALERT! WATCHING FOR ANOTHER RUN LIKE YESTERDAY, BUT TODAY WITH NEWS OUT!!
SAP, in Cooperation with The Pulse Network, Inc., Announces the Upcoming Live 'Customer Edge' Webisode for December 12, 2013
$TPNI ON HIGH ALERT, NEWS OUT
CANTON, MA, Dec. 4, 2013 (GLOBE NEWSWIRE) -- The Pulse Network, Inc. (TPNI), a digital media and event solutions company, in cooperation with SAP, the market leader in enterprise application software, announces the next Customer Edge webisode for December 12, 2013. The webisode will focus on the adoption of customer experience technologies in the enterprise with a leading panel of experts.
The Customer Edge is a new multimedia resource for all things related to delivering engaging, profitable customer relationships - for marketers, sales professionals and service executives. With exclusive video content, feature articles, social feeds and conversations, The Customer Edge is your one-stop shop for learning, sharing and networking with peers, all from your desktop, tablet or smartphone. Subscribers to The Customer Edge also get exclusive access to all video content, white papers and newsletters covering the latest updates. This growing community of marketing, sales and service professionals, stays up to date with industry news, case studies, discussions, expert opinions and how-to guides.
$TPNI ON HIGH ALERT, NEWS OUT ! WATCHING FOR ANOTHER RUN LIKE YESTERDAY!
$TPNI On High Alert! Hit .29 yesterday on pure momentum, watching what its going to do with news and a huge buzz!!
from these levels hitting .29 again is 70+% !
ALL IMO
$ISCO up 3.4% moving! watching for a push after lunch into the end of the day
$ISCO UP 3.4% watching for a push after lunch
$ISCO ON HIGH ALERT UP 2+% PRE MARKET ! CHECK IT OUT
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology.
$ISCO WITH PRE MARKET VOLUME UP 2.47%
$ISCO UP 2+% PRE MARKET !
$ISCO ON YOUR RADAR RIGHT NOW! CHECK OUT LEVEL 2 MOVING UP
$ISCO MOVING UP PRE MARKET ! ON HIGH ALERT !
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology.
$ISCO ON HIGH ALERT, LEVEL TWO MOVING UP PRE MARKET !
$ISCO WATCHIGN FOR BREAK OUT TOMORROW!
$ISCO ON HIGH ALERT FOR TOMORROW! ...
ISCO Poster Selected for Presentation at American Association for the Study of Liver Diseases Meeting
The American Association for the Study of Liver Diseases (AASLD) recently highlighted International Stem Cell’s presentation, titled “Human parthenogenetic stem cell-derived hepatocyte transplantation controls serum bilirubin in Gunn rats,” as a Presidential Poster of Distinction at The Liver Meeting during the four-day AASLD’S 64th Annual Meeting in Washington, D.C.
The presentation authors are Dr. Alina Ostrowska, Dr. Larisa Agapova, Tiffany Chu, Dr. Trudy Christiansen-Weber and Dr. Ruslan Semechkin, all of which are from International Stem Cell.
International Stem Cell is a development stage biotech company focused on therapeutic applications of human stem cells as well as the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells, called parthenogenetic stem cells, created from unfertilized human eggs. In addition to its therapeutic focus, International Stem Cell also provides a growing revenue stream through two wholly owned subsidiaries.
AASLD presented the following information on the company’s liver program:
Background: Extensive studies indicate that pluripotent stem cells are a highly promising alternative source of histocompatible cells for cell replacement therapy. Hepatocyte-like cells (HLCs) derived from human parthenogenetic stem cells (hpSCs) might be transplanted to treat a wide array of metabolic liver diseases including CN1 (Crigler-Najjar syndrome type I). CN1 is the paradigm of inherited liver-based metabolic disorders in that the host liver is lacking one hepatic enzyme – UGT1A1, which is essential for the conjugation and excretion of bilirubin. To obtain ultimate proof that differentiation has been achieved, following the preliminary evaluation in vitro, we tested hepatocyte-like cells in vivo using an accurate animal model of CN1, the Gunn rats which accumulate toxic plasma levels of unconjugated bilirubin.
Methods: Highly enriched populations of definitive endoderm were generated from hpSCs in a novel 3D-differentiation system and then induced to differentiate towards HLCs. The final cells were characterized by using expression profiling including RT-qPCR for dynamic expression of the hepatic lineage genes, immunohistochemistry and FACS analysis to demonstrate hepatocyte-specific markers, drug metabolism assays to determine the activity of CYP450s as well as a luminescent method for measuring UGT activity profile. Production of liver-specific proteins in the culture medium was simultaneously measured by quantitative ELISA. To evaluate engraftment and functional repopulation in vivo, CFSE-labeled hpHC were injected (10×106 per animal) into the spleen of 4-6 week old Gunn rats. Blood serum samples of tested animals were evaluated for indirect bilirubin levels 4, 8 and 19 weeks post-transplantation. Liver tissue samples were embedded in OCT compound and snap frozen, until cryosectioning.
Results: CFSE-labeled HLCs transferred into the spleen were shown to migrate into the liver. Multiple engrafted cells were observed in the periportal regions of the liver lobules and formed morphologically distinct aggregates. The overall liver structure appeared undamaged without signs of inflammation, fibrosis or tumor. Significant decrease and long-term stabilization of bilirubin levels was demonstrated in the serum of tested animals in comparison with sham-treated controls. Although by week 19th serum indirect bilirubin was not normalized in transplanted animals, it resulted in an average 70% reduction compared with pretreatment levels.
Conclusion: This pre-clinical study describes important supportive evidence of the potential efficacy and safety of hpSC-derived hepatocytes which might constitute an easily available source to obtain a large number of transplantable cells for regenerative treatments of CN1. In the long-term, experience with HLCs transplantation for CN1 can be used to develop therapeutic strategies for more common inherited liver diseases.
For more information, visit www.internationalstemcell.com
$ISCO ON RADAR TOMORROW ! WATCHING FOR HUGE BREAK OUT!...
ISCO Poster Selected for Presentation at American Association for the Study of Liver Diseases Meeting
The American Association for the Study of Liver Diseases (AASLD) recently highlighted International Stem Cell’s presentation, titled “Human parthenogenetic stem cell-derived hepatocyte transplantation controls serum bilirubin in Gunn rats,” as a Presidential Poster of Distinction at The Liver Meeting during the four-day AASLD’S 64th Annual Meeting in Washington, D.C.
The presentation authors are Dr. Alina Ostrowska, Dr. Larisa Agapova, Tiffany Chu, Dr. Trudy Christiansen-Weber and Dr. Ruslan Semechkin, all of which are from International Stem Cell.
International Stem Cell is a development stage biotech company focused on therapeutic applications of human stem cells as well as the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells, called parthenogenetic stem cells, created from unfertilized human eggs. In addition to its therapeutic focus, International Stem Cell also provides a growing revenue stream through two wholly owned subsidiaries.
AASLD presented the following information on the company’s liver program:
Background: Extensive studies indicate that pluripotent stem cells are a highly promising alternative source of histocompatible cells for cell replacement therapy. Hepatocyte-like cells (HLCs) derived from human parthenogenetic stem cells (hpSCs) might be transplanted to treat a wide array of metabolic liver diseases including CN1 (Crigler-Najjar syndrome type I). CN1 is the paradigm of inherited liver-based metabolic disorders in that the host liver is lacking one hepatic enzyme – UGT1A1, which is essential for the conjugation and excretion of bilirubin. To obtain ultimate proof that differentiation has been achieved, following the preliminary evaluation in vitro, we tested hepatocyte-like cells in vivo using an accurate animal model of CN1, the Gunn rats which accumulate toxic plasma levels of unconjugated bilirubin.
Methods: Highly enriched populations of definitive endoderm were generated from hpSCs in a novel 3D-differentiation system and then induced to differentiate towards HLCs. The final cells were characterized by using expression profiling including RT-qPCR for dynamic expression of the hepatic lineage genes, immunohistochemistry and FACS analysis to demonstrate hepatocyte-specific markers, drug metabolism assays to determine the activity of CYP450s as well as a luminescent method for measuring UGT activity profile. Production of liver-specific proteins in the culture medium was simultaneously measured by quantitative ELISA. To evaluate engraftment and functional repopulation in vivo, CFSE-labeled hpHC were injected (10×106 per animal) into the spleen of 4-6 week old Gunn rats. Blood serum samples of tested animals were evaluated for indirect bilirubin levels 4, 8 and 19 weeks post-transplantation. Liver tissue samples were embedded in OCT compound and snap frozen, until cryosectioning.
Results: CFSE-labeled HLCs transferred into the spleen were shown to migrate into the liver. Multiple engrafted cells were observed in the periportal regions of the liver lobules and formed morphologically distinct aggregates. The overall liver structure appeared undamaged without signs of inflammation, fibrosis or tumor. Significant decrease and long-term stabilization of bilirubin levels was demonstrated in the serum of tested animals in comparison with sham-treated controls. Although by week 19th serum indirect bilirubin was not normalized in transplanted animals, it resulted in an average 70% reduction compared with pretreatment levels.
Conclusion: This pre-clinical study describes important supportive evidence of the potential efficacy and safety of hpSC-derived hepatocytes which might constitute an easily available source to obtain a large number of transplantable cells for regenerative treatments of CN1. In the long-term, experience with HLCs transplantation for CN1 can be used to develop therapeutic strategies for more common inherited liver diseases.
For more information, visit www.internationalstemcell.com
BIG BUZZ AROUND IT TONIGHT, ALOT OF EXPOSURE ON FACEBOOK GROUPS AND TWITTER... TOMORROW SHOULD BE AN INTERESTING DAY ! GL AND ALL IMO
$ISCO ON HIGH ALERT! WATCHING FOR A MOVE BACK TO 52WK HIGH OF .41
About International Stem Cell Corp.
International Stem Cell Corp. is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
For more information visit http://www.internationalstemcell.com/
$ISCO On High Alert for tomorrow, watching for a break out
?$ISCO ON HIGH ALERT
ISCO Huge Highlights: Strong 3rd Quarter Revenues and Growth!
Record revenues of $1.67 mill, a 41% increase over the corresponding period of 2012. Lifeline Skin Care sales up 54% and Lifeline Cell Technology sales up 30%. Gross margin stable at 73%.Net cash used in operating cash flows (which exclude capital expenditures and patent costs), reduced to approximately $0.47 million per month compared to $0.57 mil per month the corresponding period of 2012.Entered into a clinical research agreement with Duke University for the evaluation of ISCO's stem cell-derived neural stem cells for the treatment of Parkinson's disease. Prof. Mark Stacy, M.D., Vice Dean for Clinical Research, Neurology at Duke University School of Medicine and an internationally recognized leader in the field of Movement Disorders, will be the principal investigator.Convened a key opinion leader meeting bringing together leading experts from throughout North America in the field of cell therapy and movement disorders to obtain feedback and guidance for the IND submission in 2014 for our stem cell-derived neural stem cells for the treatment of Parkinson's disease.Presented the results of the first primate study, carried out in collaboration with the Sanford Burnham Institute of Regenerative Medical, examining the benefits of implanting neural stem cells into primates with chemically-induced parkinsonian symptoms, at the American Neurological Association 2013 Annual Meeting.
ISCO is Commited To Parkinsons Disease Program!
?
ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC) which are a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (i) differentiate into dopaminergic (DA) neurons and (ii) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's disease, especially in cases where current small molecule approaches fail to adequately control the symptoms.
?
? $3.00 Mill of obtained gross proceeds?through a public offering, to be used to fund R&D programs
?
Simon Craw, ISCO's?Executive Vice President of Business Development, stated:?"In July we raised approximately $3 million, most of which came from a group of new investors new to ISCO. The capital will be used to fund our R&D programs, primarily our Parkinson's disease program where we intend to start a clinical trial in 2014."
$ISCO On Radar ...
ISCO Huge Highlights: Strong 3rd Quarter Revenues and Growth!
Record revenues of $1.67 mill, a 41% increase over the corresponding period of 2012. Lifeline Skin Care sales up 54% and Lifeline Cell Technology sales up 30%. Gross margin stable at 73%.Net cash used in operating cash flows (which exclude capital expenditures and patent costs), reduced to approximately $0.47 million per month compared to $0.57 mil per month the corresponding period of 2012.Entered into a clinical research agreement with Duke University for the evaluation of ISCO's stem cell-derived neural stem cells for the treatment of Parkinson's disease. Prof. Mark Stacy, M.D., Vice Dean for Clinical Research, Neurology at Duke University School of Medicine and an internationally recognized leader in the field of Movement Disorders, will be the principal investigator.Convened a key opinion leader meeting bringing together leading experts from throughout North America in the field of cell therapy and movement disorders to obtain feedback and guidance for the IND submission in 2014 for our stem cell-derived neural stem cells for the treatment of Parkinson's disease.Presented the results of the first primate study, carried out in collaboration with the Sanford Burnham Institute of Regenerative Medical, examining the benefits of implanting neural stem cells into primates with chemically-induced parkinsonian symptoms, at the American Neurological Association 2013 Annual Meeting.
ISCO is Commited To Parkinsons Disease Program!
?
ISCO's Parkinson's disease program uses human parthenogenetic neural stem cells (hPNSC) which are a novel therapeutic cellular product derived from the company's proprietary histocompatible human pluripotent stem cells. hPNSC are self-renewing mulitpotent cells that are precursors for the major cells of the central nervous system. The ability of hPNSC to (i) differentiate into dopaminergic (DA) neurons and (ii) express neurotrophic factors such as glial derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF) to protect the nigrostriatal system, offers a new opportunity for the treatment of Parkinson's disease, especially in cases where current small molecule approaches fail to adequately control the symptoms.
?
? $3.00 Mill of obtained gross proceeds?through a public offering, to be used to fund R&D programs
?
Simon Craw, ISCO's?Executive Vice President of Business Development, stated:?"In July we raised approximately $3 million, most of which came from a group of new investors new to ISCO. The capital will be used to fund our R&D programs, primarily our Parkinson's disease program where we intend to start a clinical trial in 2014."
$IOGA ON RADAR RIGHT NOW!
$IOGA ON HIGH ALERT THIS MORNING, WATCHING FOR A STRONG MOVE!
LAS VEGAS, NV--(Marketwired - Nov 19, 2013) - Inscor, Inc. (PINKSHEETS: IOGA) CEO, Kenny Andam, has added another professional to the company's newly formed sports division. The CEO announced today that Phil Sloan has joined sports division President, John Salley, to market and generate sales of the company's Financed Insurance Trust (FIT) plan.
Phil Sloan, a graduate of Harvard University, has spent the past 7 years in the public relations industry with top firms in both New York and Boston. Sloan learned the industry, creative marketing, sales and created client relationships from the world of professional sports while working with Hill & Knowlton, one of the oldest and most prestigious New York-based public relations firms, and at the firms Mullen and Arnold Worldwide, Boston's largest advertising and public relations agencies.
$IOGA ON HIGH ALERT FOR THIS MORNING ! PUT IT ON YOUR RADAR ! WATCHING FOR A STRONG MOVE!
About INSCOR, Inc.
INSCOR, Inc. specializes in the creation and implementation of flexible and effective insurance solutions for organizations serving as many as tens of millions of members across the globe. In the U.S., the Company markets its FIT OPEB plan to municipalities and corporations as a low-cost solution to funding retiree and other employee benefits. A Financed Insurance Trust plan variation also works for affluent individuals, entertainers and professional athletes -- whether for estate planning or funding cash flow needs. INSCOR's strategy uses a combination of favorable financing terms, innovative uses of specific life insurance products and trusts -- all of which result in minimum levels of out-of-pocket costs for producing significant future funding and revenue stream opportunities. For more information: www.ins-cor.com
$IOGA ON HIGH ALERT THIS MORNING! WATCHING FOR ANOTHER RALLY HERE ALL IMO
$PLPL watching for a major rally from these keveks, check out chart and see past runs from around these levels... last time we featured it it was a huge winner !
$PLPL on watch for next rally ! On high alert this morning !
$PLPL on high alert this morning !
$PLPL ON CLOSE WATCH FOR A POTENTIAL RALLY FROM HERE !ALL IMO
Company Credo
Customers
Our first priority is to our customers. To provide them with the best possible product. To make the product accessible to all who require it, and at a fair price.
Employees
To all our staff, with what you bring to the company, you are unique. You are part of our family and we are part of yours. All of you will be recognized for what you do for the company and will be rewarded as such. We all have the same devotion to the company and its clients. We all can proudly say that we are part of an organization that makes a difference in someone’s life. Be proud about that fact because without you as an individual it would not be possible.
Community & the Environment
Without the support of the community we would not have achieved what we have to date. As such we are now part of the community. This means that we now have a responsibility to uplift the community, where possible.
We are indebted to the environment for providing us with raw material to create our product. It is our responsibility to ensure that our environment is kept in the most pristine condition possible so as to further supply us with our needs and wants.
Stockholders
Our final responsibility is to our stockholders, when we have taken care of our customers, employees, the community and the environment. We must experiment with new ideas. Research must be done in order to grow the organization. Reserves must be created to weather adverse times.
When we follow these principles stockholders will realize a fair return.
$PLPL ON HIGH ALERT FOR TOMORROW!
TOMORROW COULD BE A HUGE DAY FOR THE STOCK IMO
Plandaí Biotechnology, Inc. intends to transform the world of nutraceuticals by making available extracts from live plant material that deliver the highest levels of bioavailability currently in the market. Our headquarters are in Seattle, Washington, USA. Although we also have a global presence with offices in London, England and Nelspruit in the province of Mpumalanga, South Africa. This enables us to react more efficiently to any worldwide market changes as well as to any customer requirements.
Plandaí Biotechnology is the culmination of over ten years of research in the field of plant extracts. Its principle holdings consist of land, farms and infrastructure, totaling more than 8500 acres, in the province of Mpumalanga, South Africa.
$PLPL ON HIGH ALERT FOR TOMORROW! WATCHING FOR A RALLY AGAIN !
Products and benefits
"BIOAVAILABILITY" can be defined as a measurement of the amount of compound absorbed into the bloodstream.
In the market today, green tea high purity EGCG extracts, with an average selling price of $500/kg, have poor bioavailability of between 1-10%. Plandaí proprietary plant extracts has shown, in published studies, to have increased bioavailability. We believe through our studies that this is between 60-80%, far exceeding anything currently available today.
Our extracts include but are not limited to, gallate catechins from green tea, (catechin gallate (CG),epigallocatechin gallate (EGCG), gallocatechin gallate (GCG), and epicatechin gallate (ECG); carotenoids (lycopene)from tomatoes, as well as citrus bioflavonoids and limonoids. Furthermore, Plandaí's gallate catechin extract will be the active ingredient in formulated products supporting weight loss, antiaging, the lowering of blood cholesterol, the regulation of high blood pressure and controlling diabetes 1 and 2.
This means, that Plandaí's extracts deliver a more meaningful and beneficial dose at highly competitive prices to the consumer, in wellness terms
The Northern American and European natural extracts market are emerging and in a state of intense competition. The shift towards natural ingredients is driving the expansion of the natural extracts market. Among the flurry of ingredients competing in the natural extracts market, green tea extracts is a pioneer and one of the most prominent success stories. (Frost & Sullivan Research, 2011)
$PLPL On high Alert For Tomorrow! We are watching for a major rally here AGAIN!
CEYY #10 on break out boards can it get to #1?
CEYY moving up on break out boards